Neurocrine Biosciences Inc's Form 4 filing
Voyager Therapeutics, Inc.VYGR · filed Feb 24, 2023
- Accession no.
- 0000899243-23-006093
- Filed
- Feb 24, 2023
- Trade date
- Feb 23, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $39.0M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Neurocrine Biosciences IncCIK 0000914475 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 23, 2023 | Common Stock | PPurchaseAcquired | +4,395,588 | $8.88F1 | +$39,032,821.44 | 8,575,316 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The purchase price was determined in accordance with that certain Stock Purchase Agreement dated January 8, 2023, between the reporting person and the issuer.
Referenced by the price of 1 transaction in Table I.